McKesson releases 3Q FY05 results

McKesson Corp. reported that revenues for the third quarter FY05 ending December 31 were $20.8 billion, an increase of 14 percent from $18.2 billion in the year-ago quarter.
   
For the quarter, McKesson had a net loss of $655 million including the previously announced after tax-charge of $810 million for settling the company's consolidated securities class action and reserves for remaining related cases. Not including the securities litigation charge, McKesson had net income of $145 million compared with $120 million in the year-ago quarter.
   
For the nine-month period, sales increased 16 percent to $59.9 million, compared with $51.6 million in the first nine months of FY04. Net income, excluding securities litigation charge decreased 9 percent to $394.3 million, compared with $432.3 million in the year-ago period.

Around the web

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.